Dr Frederick H. hausheer was appointed chief medical officer by Wuxi apptec

April 8, 2019 / AP / -- Wuxi apptec today announced that Dr Frederick H hausheer has officially joined the company as chief medical officer Dr hausheer will lead the medical, scientific and operational management of the clinical development services business of Wuxi apptec in the United States, China and around the world In addition, he will provide the company with strategic guidance in medical and clinical development, so as to strengthen the close contact between business departments and partners, and promote the seamless connection from preclinical transformation research and development, to the first human clinical trial (FIH), to the one-stop service platform for customers to develop phase I-IV clinical development plan Dr hausheer has more than 30 years of business and academic experience in clinical drug development, transformation science and medicine of cancer worldwide He has rich experience in transformation research / new drug clinical trial application, clinical trial design, commercial clinical development and other fields He has participated in the supervision and communication work from the early stage of new drug clinical trial application to phase I-III clinical trial The project covers Europe, the United States, China, Japan and other countries and regions "We very much welcome Dr hausheer to join us as chief medical officer," said Mr Hu Zhengguo, CO CEO of Wuxi apptec "Dr hausheer has rich experience in global tumor drug development, clinical research and medical fields It is believed that his joining will further enhance the company's clinical service capacity and scale in the world, better empower global customers, and promote the emergence of more new and good drugs as soon as possible, so as to benefit patients " Prior to joining Wuxi apptec, Dr hausheer served as CEO and chief medical officer of several biopharmaceutical companies He was the founder and chairman of bio Numerik pharmaceuticals He is also a member of the business advisory committee of JPMorgan Chase, Whitaker Institute at Johns Hopkins University, National Cancer Institute (NCI) and other organizations In his early career, Dr hausheer served in NCI's experimental treatment department, decision-making network group and institutional review committee, and extensively participated in many national and international clinical phase I-III trial projects, involving innovative therapies for lung cancer, breast cancer, ovarian cancer and other malignant tumors Dr hausheer received his M.D from the University of Missouri School of medicine and worked at Johns Hopkins cancer center after graduation, focusing on innovative experimental therapies and pharmacology At present, Dr hausheer is also an adjunct professor of oncology at the University of Missouri and Johns Hopkins cancer center In addition, he is the inventor or co inventor of more than 400 US and international patents As a leading open capability and technology platform company in the world, Wuxi apptec provides all-round integrated laboratory R & D and production services from drug discovery, development to marketization in the fields of global pharmaceutical and medical devices With the purpose of taking research as the first task and customer as the center, Wuxi apptec helps global customers shorten the R & D cycle of drugs and medical devices and reduce the R & D cost through a cost-effective and efficient service platform The platform includes small molecule drug R & D and production, cell therapy and gene therapy R & D and production, medical device testing, etc it is carrying thousands of R & D and innovation projects from more than 3500 innovation partners from more than 30 countries around the world, and is committed to bringing the latest and best medicine and health products to patients around the world, so as to realize "no hard medicine, no hard disease to treat" ”Dream of.